Translational sub-studies
Cancer
CANCER
Translational work within REFINE aims to understand the pharmacokinetic and pharmacodynamic aspects of extended versus standard interval ICI, conducted in collaboration with Imperial College London and the US National Cancer Institute (NCI). Serial blood samples will be collected from approximately 80 patients (40 from SOC and 40 from extended interval) during their first 9 months on study. Pharmacokinetic analysis of therapeutic drug levels and flow cytometry to determine T cell receptor occupancy will determine whether extended interval dosing influences T cell activation. Consent for this sub- study is optional.